CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

211448Orig1s000

Trade Name:	Mezofy oral film
Generic or Proper Name:	aripiprazole
Sponsor:	CMG Pharmaceutical Co., Ltd
Approval Date:	April 15, 2025
Indication:	For the treatment of schizophrenia.

CENTER FOR DRUG EVALUATION AND RESEARCH

211448Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Officer/Employee List	**X**
Multidiscipline Review(s) • **Summary Review** • **Clinical** • **Non-Clinical** • **Statistical** • **Clinical Pharmacology**	**X**
Product Quality Review(s)	**X**
Clinical Microbiology / Virology Review(s)	
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

211448Orig1s000

APPROVAL LETTER

NDA 211448

NDA APPROVAL

CMG Pharmaceutical Co., Ltd
C/O Premier Research Consulting, LLC
Attn: Tony Phillips
Project Manager, Premier Consulting
8000 Jarvis Ave, Suite 100
Newark, CA 94560

Dear Tony Phillips:

Please refer to your new drug application (NDA) received October 18, 2019, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mezofy (aripiprazole) oral film.

We acknowledge receipt of your amendment dated October 15, 2024, which constituted a complete response to our August 18, 2020, action letter.

This NDA provides for the use of Mezofy (aripiprazole) oral soluble film for the treatment of schizophrenia.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry, *SPL Standard for Content of Labeling Technical Qs and As.*[2]

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry, *SPL Standard for Content of Labeling Technical Qs & As.* For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved NDA 211448**." Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Mezofy (aripiprazole) oral film shall be 36 months from the date of manufacture when stored at 20° to 25°C.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA; 21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for younger than 13 years of age because necessary studies are impossible or highly impracticable. This is because childhood onset schizophrenia is rare, with an incidence less than 0.04%.[3] The number of available patients is so small that studies are impossible or highly impractical.

The available dosage strengths of Mezofy do not allow for initiation at the recommended starting dose of 2 mg daily for pediatric patients 13 to 17 years of age with schizophrenia. We require you to develop a 2-mg strength to fulfill this need and are deferring this requirement at this time because this product is otherwise ready for approval.

[3] Driver DI, Thomas S, Gogtay N, Rapoport JL. Childhood-onset schizophrenia and early-onset schizophrenia spectrum disorders: an update. Child and Adolescent Psychiatric Clinics. 2020 Jan 1;29(1):71-90.

Your deferred pediatric requirement is required under section 505B(a) of the Federal Food, Drug, and Cosmetic Act. The status of this postmarketing requirement must be reported annually according to 21 CFR 601.28 and Section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act.

PMR 4828-1 Develop a 2-mg strength of Mezofy to meet the need for initial dose titration in pediatric patients ages 13 to 17 years with schizophrenia.
Completion date/supplement submission date: April 30, 2027

Development of a 2-mg strength of the oral film include formulation development, manufacturing, associated pharmaceutical testing, generation of adequate stability data, and collection of adequate data supporting a biowaiver for this strength.

The supplemental NDA PMR submission should include a biowaiver request for the proposed 2-mg strength Mezofy oral film, with the appropriate CFR citation and supporting information including evidence of (1) in vitro dissolution profiles similarity when compared to the approved 10-mg strength, (2) similar disintegration times, (3) formulation composition proportionality of the 2-mg strength oral film to the 10-mg oral film in terms of the type and quantities of the active and inactive ingredients, and (4) any information regarding dose proportionality/PK linearity covering the therapeutic dose range. Note that the adequacy of the biowaiver request will be determined during supplemental NDA review.

Response to this required pediatric postmarketing requirement must be submitted as a supplement to your approved NDA with the proposed labeling changes you believe are warranted. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry, *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*[4]

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication,

[4] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.

accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.[5] Information and Instructions for completing the form can be found at FDA.gov.[6]

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website.[7]

If you have any questions, contact Pawanprit Singh, Regulatory Project Manager, at Pawanprit.singh@fda.hhs.gov or 240-402-8866.

Sincerely,

{See appended electronic signature page}

Bernard Fischer, MD
Deputy Director
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Instructions for Use
- Carton and Container Labeling

[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[6] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf
[7] https://www.uspnf.com/

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BERNARD A FISCHER
04/15/2025 03:54:02 PM